{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:13:03Z","timestamp":1778577183902,"version":"3.51.4"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Hyperphosphatemia is present in nearly all patients with kidney failure who receive maintenance dialysis. The direct toxicity of elevated phosphate concentrations had been inferred from basic experimentation and large epidemiologic studies. This has influenced clinical practice in which great efforts are expended in normalizing serum phosphate concentration. Targeted dietary strategies, optimization of dialysis and phosphate-lowering medications are all effective at lowering serum phosphate levels yet each pose challenges for patients and clinicians. The effect of these interventions, individually and collectively, on patient-centered clinical outcomes is also unclear. We will review the evidence from clinical trials for each of these measures and discuss ongoing research that is testing optimal targets for serum phosphate.<\/jats:p>","DOI":"10.1093\/ckj\/sfag108","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:40:36Z","timestamp":1775302836000},"source":"Crossref","is-referenced-by-count":0,"title":["Phosphate\u2014latest news and ongoing trials"],"prefix":"10.1093","volume":"19","author":[{"given":"Arti Sharma","family":"Parpia","sequence":"first","affiliation":[{"name":"Division of Nephrology, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Kumra","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Manitoba , Winnipeg, MB ,","place":["Canada"]},{"name":"St. Boniface Hospital Department of Pharmacy, , Winnipeg, MB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Mansell","sequence":"additional","affiliation":[{"name":"Faculty of Arts and Sciences, Washington University St. Louis , St. Louis, MO ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziv","family":"Harel","sequence":"additional","affiliation":[{"name":"Division of Nephrology, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Perl","sequence":"additional","affiliation":[{"name":"Division of Nephrology, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-1717","authenticated-orcid":false,"given":"Orit Kliuk","family":"Ben-Bassat","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center Department of Nephrology and Hypertension, , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-8169","authenticated-orcid":false,"given":"Ron","family":"Wald","sequence":"additional","affiliation":[{"name":"Division of Nephrology, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital , Toronto, ON ,","place":["Canada"]},{"name":"Tel Aviv Sourasky Medical Center Department of Nephrology and Hypertension, , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"2026051204320273700_bib1","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1093\/ndt\/gft244","article-title":"Phosphate control in end-stage renal disease: barriers and opportunities","volume":"28","author":"Waheed","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026051204320273700_bib2","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"2026051204320273700_bib3","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"key":"2026051204320273700_bib4","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.2215\/CJN.0000000733","article-title":"Vascular calcification and CKD: challenges, emerging targets, and future perspectives","volume":"20","author":"Fernandez","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"key":"2026051204320273700_bib6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib7","doi-asserted-by":"publisher","first-page":"20543581241238808","DOI":"10.1177\/20543581241238808","article-title":"Pathways for diagnosing and treating CKD-associated pruritus: a narrative review","volume":"11","author":"Rigatto","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"2026051204320273700_bib8","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2026051204320273700_bib9","first-page":"1","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7h","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"2026051204320273700_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ndt\/gfad188","article-title":"The basics of phosphate metabolism","volume":"39","author":"Wagner","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026051204320273700_bib11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2215\/CJN.11901115","article-title":"Phosphate toxicity in CKD: the killer among us","volume":"11","author":"Ritter","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2016.03.039","article-title":"Phosphate\u2014a poison for humans?","volume":"90","author":"Komaba","year":"2016","journal-title":"Kidney Int"},{"key":"2026051204320273700_bib13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2215\/CJN.01610214","article-title":"Setting research priorities for patients on or nearing dialysis","volume":"9","author":"Manns","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2026051204320273700_bib17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.ajkd.2014.01.429","article-title":"Balancing nutrition and serum phosphorus in maintenance dialysis","volume":"64","author":"Fouque","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/ndt\/gfw323","article-title":"Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial","volume":"32","author":"Rhee","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026051204320273700_bib19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.numecd.2018.09.010","article-title":"The impact of a nutritional intervention based on egg white for phosphorus control in hemodialyis patients","volume":"29","author":"Guida","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026051204320273700_bib20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/hdi.13028","article-title":"The effect of egg white diet on phosphorus control in dialysis patients","volume":"26","author":"Azmandian","year":"2022","journal-title":"Hemodial Int"},{"key":"2026051204320273700_bib21","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1681\/ASN.0000000873","article-title":"ASN kidney health guidance on potassium and phosphorus food additives","volume":"36","author":"Biruete","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026051204320273700_bib22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2215\/CJN.0000000715","article-title":"Dietary phosphorus and metabolic health in CKD and ESKD","volume":"20","author":"Cupisti","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2009.96","article-title":"Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial","volume":"301","author":"Sullivan","year":"2009","journal-title":"JAMA"},{"key":"2026051204320273700_bib24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.jrn.2016.08.009","article-title":"Replacing phosphorus-containing food additives with foods without additives reduces phosphatemia in end-stage renal disease patients: a randomized clinical trial","volume":"27","author":"de\u00a0Fornasari","year":"2017","journal-title":"J Ren Nutr"},{"key":"2026051204320273700_bib25","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.ekir.2020.08.008","article-title":"Pilot randomized controlled trial of a standard versus a modified low-phosphorus diet in hemodialysis patients","volume":"5","author":"Byrne","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026051204320273700_bib26","first-page":"CD010350","article-title":"Dietary interventions for mineral and bone disorder in people with chronic kidney disease","volume":"2015","author":"Liu","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051204320273700_bib27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2215\/CJN.09360620","article-title":"Effect of phosphate-specific diet therapy on phosphate levels in adults undergoing maintenance hemodialysis: a systematic review and meta-analysis","volume":"16","author":"St-Jules","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/sdi.13112","article-title":"Comparison of modeled versus reported phosphate removal and modeled versus postdialysis serum phosphate levels in conventional hemodialysis","volume":"36","author":"Daugirdas","year":"2023","journal-title":"Semin Dial"},{"key":"2026051204320273700_bib29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/sdi.12439","article-title":"Removal of phosphorus by hemodialysis","volume":"28","author":"Daugirdas","year":"2015","journal-title":"Semin Dial"},{"key":"2026051204320273700_bib30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.ki.5002750","article-title":"Impact of hemodialysis duration on the removal of uremic retention solutes","volume":"73","author":"Eloot","year":"2008","journal-title":"Kidney Int"},{"key":"2026051204320273700_bib31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1681\/ASN.2011070688","article-title":"Effects of frequent hemodialysis on measures of CKD mineral and bone disorder","volume":"23","author":"Daugirdas","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026051204320273700_bib32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/ndt\/gfq724","article-title":"Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study","volume":"26","author":"Ok","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026051204320273700_bib33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1681\/ASN.2011070674","article-title":"Survival with three-times weekly in-center nocturnal versus conventional hemodialysis","volume":"23","author":"Lacson","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026051204320273700_bib34","first-page":"369","article-title":"The association between conversion to in-centre nocturnal hemodialysis and left ventricular mass regression in patients with end-stage renal disease","volume":"32","author":"Wald","year":"2016","journal-title":"Can J Cardiol"},{"key":"2026051204320273700_bib35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jama.298.11.1291","article-title":"Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial","volume":"298","author":"Culleton","year":"2007","journal-title":"JAMA"},{"key":"2026051204320273700_bib36","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1093\/ndt\/gfac223","article-title":"Comparison of measured vs kinetic-model predicted phosphate removal during hemodialysis and hemodiafiltration","volume":"37","author":"Daugirdas","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026051204320273700_bib37","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000920","article-title":"The role of online hemodiafiltration in contemporary kidney care","author":"Ronco","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib38","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1093\/ndt\/gfaf024","article-title":"Haemodiafiltration versus high-flux haemodialysis\u2014a consensus statement from the EuDial working group of the ERA","volume":"40","author":"Battaglia","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026051204320273700_bib39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11255-012-0324-8","article-title":"Effects of high-efficiency postdilution online hemodiafiltration and high-flux hemodialysis on serum phosphorus and cardiac structure and function in patients with end-stage renal disease","volume":"45","author":"Francisco","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"2026051204320273700_bib40","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1056\/NEJMoa2304820","article-title":"Effect of hemodiafiltration or hemodialysis on mortality in kidney failure","volume":"389","author":"Blankestijn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051204320273700_bib41","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1046\/j.1523-1755.2003.00310.x","article-title":"Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms","volume":"64","author":"Bammens","year":"2003","journal-title":"Kidney Int"},{"key":"2026051204320273700_bib42","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2215\/CJN.00190108","article-title":"Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics","volume":"3","author":"Badve","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2215\/CJN.06960810","article-title":"Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis","volume":"6","author":"Bernardo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib44","doi-asserted-by":"publisher","first-page":"e0257140","DOI":"10.1371\/journal.pone.0257140","article-title":"Peritoneal dialysis modality transition and impact on phosphate and potassium serum levels","volume":"16","author":"Peruzzo","year":"2021","journal-title":"PLoS One"},{"key":"2026051204320273700_bib45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1525-139X.2011.00849.x","article-title":"The phosphate binder equivalent dose","volume":"24","author":"Daugirdas","year":"2011","journal-title":"Semin Dial"},{"key":"2026051204320273700_bib46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJM198607173150304","article-title":"Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis","volume":"315","author":"Slatopolsky","year":"1986","journal-title":"N Engl J Med"},{"key":"2026051204320273700_bib47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MNH.0000000000000796","article-title":"Non calcium phosphate binders\u2014is there any evidence of benefit","volume":"31","author":"Jadav","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026051204320273700_bib48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"2026051204320273700_bib49","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"2026051204320273700_bib50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5414\/CNP62193","article-title":"Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis","volume":"62","author":"Finn","year":"2004","journal-title":"Clin Nephrol"},{"key":"2026051204320273700_bib51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5414\/CNP65191","article-title":"Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients","volume":"65","author":"Finn","year":"2006","journal-title":"Clin Nephrol"},{"key":"2026051204320273700_bib52","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/jama.2021.4807","article-title":"Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"key":"2026051204320273700_bib53","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"Wuthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib54","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"2026051204320273700_bib55","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026051204320273700_bib56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial","volume":"66","author":"Van\u00a0Buren","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000531869","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia: a randomised, open-label, multicentre, 12-week phase III study","volume":"148","author":"Liu","year":"2024","journal-title":"Nephron"},{"key":"2026051204320273700_bib58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/ASN.2020050598","article-title":"Optimal phosphate control for coronary artery calcification in dialysis patients","volume":"32","author":"Isaka","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026051204320273700_bib59","doi-asserted-by":"publisher","first-page":"732","DOI":"10.34067\/KID.0000000000000387","article-title":"Tenapanor as therapy for hyperphosphatemia in maintenance dialysis patients: results from the OPTIMIZE study","volume":"5","author":"Sprague","year":"2024","journal-title":"Kidney360"},{"key":"2026051204320273700_bib60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000546265","article-title":"Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short-term randomized controlled trials","author":"Khan","year":"2025","journal-title":"Am J Nephrol"},{"key":"2026051204320273700_bib61","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026051204320273700_bib62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1053\/j.ajkd.2017.09.007","article-title":"Phosphate-binder use in US dialysis patients: prevalence, costs, evidence, and policies","volume":"71","author":"St\u00a0Peter","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib63","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.ajkd.2017.08.029","article-title":"Stuck in a bind with phosphate binders","volume":"71","author":"Kestenbaum","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib64","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"6","author":"Natale","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051204320273700_bib65","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.ajkd.2020.10.008","article-title":"Design and rationale of HiLo: a pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialysis","volume":"77","author":"Edmonston","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026051204320273700_bib66","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1681\/ASN.0000000765","article-title":"Higher versus lower phosphate targets for patients undergoing in-center hemodialysis: a randomized controlled trial","volume":"36","author":"Edmonston","year":"2025","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag108\/67872088\/sfag108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/5\/sfag108\/67872088\/sfag108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/5\/sfag108\/67872088\/sfag108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:32:18Z","timestamp":1778574738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag108\/8607827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag108","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,6]]},"article-number":"sfag108"}}